PainReform (PRFX) News Today $5.30 -5.86 (-52.51%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period PainReform (NASDAQ:PRFX) Stock Quotes, Forecast and News SummaryDecember 20 at 6:03 PM | benzinga.comPainReform Ltd. Navigates Leadership Changes and Nasdaq ComplianceDecember 5, 2024 | markets.businessinsider.comPainReform announces data for PRF-110 Phase 3 trial, notes incoherence of dataNovember 22, 2024 | markets.businessinsider.comPainReform (PRFX) Receives a Hold from Maxim GroupNovember 22, 2024 | markets.businessinsider.comPainReform Ltd: PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNovember 21, 2024 | finanznachrichten.dePainReform Stock Is Soaring Tuesday: What's Going On?November 21, 2024 | benzinga.comPainReform’s PRF-110 Shows Promise in Initial Trial ResultsNovember 21, 2024 | markets.businessinsider.comPainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialNovember 20, 2024 | globenewswire.comPainReform Announces 1-for-4 Reverse Share SplitNovember 18, 2024 | markets.businessinsider.comPainReform Faces Nasdaq Compliance Challenge Amid Drug DevelopmentNovember 9, 2024 | markets.businessinsider.comPainReform receives noncompliance notification from NasdaqNovember 7, 2024 | markets.businessinsider.comPainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementNovember 7, 2024 | markets.businessinsider.comPainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementNovember 7, 2024 | globenewswire.comMaxim Group Downgrades PainReform (PRFX)October 25, 2024 | msn.comPainReform cut to Hold at Maxim amid ‘changed’ market dynamicsOctober 25, 2024 | finance.yahoo.comPainReform Shares Are Trading Lower Today: What's Going OnSeptember 11, 2024 | msn.comPainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110September 11, 2024 | globenewswire.comPainReform Announces Exercise of Warrants for $1.58 Million Gross ProceedsSeptember 10, 2024 | globenewswire.comPainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy ProceduresAugust 21, 2024 | finance.yahoo.comPainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy StudyAugust 20, 2024 | globenewswire.comBuy Rating Justified by PainReform’s Promising PRF-110 with Competitive Edge and Positive Clinical DataAugust 17, 2024 | markets.businessinsider.comPainReform Provides Business Update for the Second Quarter of 2024August 15, 2024 | finance.yahoo.comPainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic EffectsAugust 12, 2024 | finance.yahoo.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Clinical DevelopmentsAugust 9, 2024 | markets.businessinsider.comPainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher DosesAugust 7, 2024 | globenewswire.comPainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110August 5, 2024 | finance.yahoo.comPainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAugust 1, 2024 | markets.businessinsider.comPainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room TemperatureAugust 1, 2024 | globenewswire.comPainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and TestingJuly 24, 2024 | finance.yahoo.comPainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 31, 2024 | globenewswire.comPainReform Ltd: PainReform Provides Business Update for the First Quarter of 2024May 16, 2024 | finanznachrichten.dePRFX Stock Earnings: PainReform Misses EPS for Q1 2024May 15, 2024 | msn.comPainReform Provides Business Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comMay 8, 2024 | globenewswire.comPainReform Announces Closing of $4 Million Public OfferingApril 18, 2024 | globenewswire.comPainReform Announces Pricing of $4 Million Public OfferingApril 16, 2024 | finance.yahoo.comEXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing ConditionsApril 9, 2024 | msn.comPainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | finance.yahoo.comPainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsApril 9, 2024 | globenewswire.comUK watchdog says Theramex-Viatris deal raises competition concernsApril 4, 2024 | finance.yahoo.comBuy Rating Affirmed for PainReform as PRF-110 Shows Promise in Non-Opioid Pain Management MarketApril 4, 2024 | markets.businessinsider.comEXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain DrugApril 2, 2024 | finance.yahoo.comPainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyApril 2, 2024 | globenewswire.comBuy Rating for PainReform’s PRF-110: Promising Non-Opioid Pain Solution Amidst Opioid CrisisMarch 7, 2024 | markets.businessinsider.comPainReform Provides Year-End Business UpdateMarch 1, 2024 | globenewswire.comPainReform to Present at the Microcap Conference in Atlantic CityJanuary 22, 2024 | finance.yahoo.comPainReform files to sell 968,545 ordinary shares for holdersJanuary 12, 2024 | msn.comBuy Rating for PainReform’s PRF-110: Superior Spreadability Signaling Market AdvantageJanuary 5, 2024 | markets.businessinsider.comPainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefJanuary 3, 2024 | finance.yahoo.comPainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsDecember 26, 2023 | finance.yahoo.com Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast. Click here for the ticker >>> PRFX Media Mentions By Week PRFX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRFX News Sentiment▼0.110.60▲Average Medical News Sentiment PRFX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRFX Articles This Week▼71▲PRFX Articles Average Week Get PainReform News Delivered to You Automatically Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBM News Today ONCT News Today GRTX News Today ERNA News Today PBLA News Today REVB News Today KRBP News Today CYTO News Today TRVN News Today SONN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRFX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PainReform Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PainReform With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRFX Stock Alerts